All In Biotech

Free tool

FAERS Monitor: Levulan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020965 or its brand name (Levulan, Aminolevulinic Acid Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,433

Serious

182

13% of reports

Hospitalization

48

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective244
  • wrong technique in product usage process182
  • poor quality product administered177
  • product quality issue153
  • product dose omission issue114
  • erythema102
  • accidental exposure to product79
  • off label use78
  • pain63
  • product physical issue62
  • blister48
  • application site pain42
  • application site erythema35
  • product packaging quantity issue34
  • skin exfoliation34

Reports by year received

View as table
YearReports
20123
20136
20146
201513
201677
201764
201887
201977
2020172
202166
2022115
2023167
2024212
2025235
2026133

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,726 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
poor quality product administeredSignal177250.7218.143,056
product physical issueSignal6245.235.52,633
product packaging quantity issueSignal3444.331.81,392
application site painSignal4228.020.81,067
application site erythemaSignal3519.614.1600
product quality issueSignal15316.614.22,232
wrong technique in product usage processSignal18213.211.52,057
blisterSignal4812.69.5500
accidental exposure to productSignal7911.39.1731
erythemaSignal1027.36.0552
skin exfoliationSignal345.94.2135
product dose omission issueSignal1145.74.8442
drug ineffectiveSignal2442.72.4281
pain631.51.210
off label use781.31.16

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.